<DOC>
	<DOCNO>NCT01533519</DOCNO>
	<brief_summary>This study design investigate safety intranasal administration NPY use dose escalation , randomize , double-blinded , placebo-controlled crossover design medication-free , symptomatic PTSD group .</brief_summary>
	<brief_title>A Dose Escalation Study Intranasal Neuropeptide Y Post Traumatic Stress Disorder ( PTSD )</brief_title>
	<detailed_description />
	<mesh_term>Stress Disorders , Traumatic</mesh_term>
	<mesh_term>Stress Disorders , Post-Traumatic</mesh_term>
	<criteria>Men woman , age 1860 . Participants must level understanding sufficient agree test examination require protocol must sign write informed consent document . We determine whether sufficient understand study procedure risk ask explain 's involve study give example study risk benefit . Participants must fulfill DSMIV criterion current PTSD , base Structured Clinical Interview DSMIV Axis I Disorders ( SCIDI ) ClinicianAdministered PTSD Scale ( CAPS ) . CAPS score must least 40 ( moderate PTSD severity ) screening . Current , primary Axis I disorder PTSD . History current bipolar disorder primary psychotic disorder ( e.g . schizophrenia , schizoaffective disorder ) . Current diagnosis anorexia nervosa bulimia nervosa . Women pregnant breastfeeding . Drug alcohol abuse dependence within precede 3 month . poorly control hypertension ( manifest SBP &gt; 140 and/or DBP &gt; 90 ) ; HR &lt; 60 &gt; 100 rest time screen confirm immediately prior randomization Evidence coronary artery disease evidence history , abnormal ECG , typical symptom History arrhythmia , cardiac surgery , family history sudden death Hepatic dysfunction define AST ALT &gt; 2x URL , alkaline phosphatase bilirubin &gt; 1.5 x URL within X day prior randomization Chronic renal disease define serum creatinine &gt; 1.9 Any serious unstable clinically significant abnormal finding laboratory parameter , physical examination , ECG determine PI . Any serious unstable condition would put subject undue risk determine PI additional safety monitor . Serious imminent suicidal homicidal risk . Psychotropic medication taper least 7 day prior screen ; withdrawal symptom must absent time screen History nasal disorder sinonasal surgery , significant nasal abnormality base nasal exam . Received investigational intervention within 30 day prior randomization</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Neuropeptide Y</keyword>
	<keyword>Intranasal Administration</keyword>
	<keyword>PTSD</keyword>
	<keyword>Trauma</keyword>
</DOC>